Perfusion medium for mammalian CHO (Chinese hamster ovary) cells and application of perfusion medium
By optimizing the components of the flow-added culture medium, a perfusion medium suitable for CHO cells was developed, which solved the complex and cost-effective development of existing perfusion medium, and achieved the effects of simple formulation, efficient expression and stable product quality.
Patent Information
- Application Number
- CN202310600050.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-25
- Publication Date
- 2024-11-26
AI Technical Summary
The existing perfusion culture medium development methods are complex and inconvenient to operate, resulting in high production costs, expensive product prices, and long perfusion culture cycle, which affects product quality stability.
Based on the basic culture medium used in flow-added culture, a perfusion culture medium with clear chemical composition is developed through component optimization, including metal compounds, sugars, vitamins, amino acids, nucleoside/nucleoside compounds, fatty acids and other ingredients, and is simple to prepare. , suitable for perfusion culture of CHO cells.
It realizes simple preparation and efficient expression of culture medium, reduces production costs, maintains cell viability and production capacity, ensures the stability of product quality, and is suitable for the wide application of CHO cells.
Smart Images

Figure CN119020257A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a perfusion culture medium for mammalian CHO cells and application thereof, belonging to the technical field of cell culture. Background Art
[0002] Mammalian cell culture, as an upstream link in biopharmaceuticals, is indispensable in the fields of antibody production, vaccine development, etc. Animal cells can be divided into suspension cells and adherent cells according to their characteristics. As for suspension cells, the current culture processes are mainly divided into traditional fed-batch culture processes and perfusion (or continuous flow) processes.
[0003] Compared with traditional fed-batch culture, perfusion culture has the main advantages of novel culture technology, high expression, small equipment footprint, and high total production capacity. It has been highly praised in the pharmaceutical industry in recent years because it can improve efficiency in an era of fierce competition. However, due to the long perfusion culture cycle, which is generally more than 20 days, it is very important to develop a perfusion culture medium that can maintain a certain cell number, viability, and production capacity, and can ensure product quality.
[0004] The development of perfusion culture medium currently on the market has the following problems: the main method is to mix the basal culture medium and feed medium used in the traditional feeding process in a certain proportion, and the mixed culture medium is used for perfusion culture, wherein the basal culture medium and feed medium need to be prepared separately, which is complicated to operate and not conducive to the scale-up culture of production. And the lack of innovation in the development by mixing commercial culture medium in proportion. For example, in the patent with application publication number CN112592948A, at different stages of culture, it is necessary to perfuse culture with different volume ratios of basal culture medium and feed medium (80-90): (10-20). In addition, Patrick Mayrhofer and David Reinhart designed a DOE (design-of-experiment) based on commercial culture media and feed supplements. According to the results of the DOE, the culture medium mixing ratio was selected as the perfusion medium (Mayrhofer P, Reinhart D, Castan A, Kunert R. Rapid development of clone-specific, high-performing perfusion media from established feed supplements. Biotechnol Prog. 2020 Mar; 36 (2): e2933.).
[0005] At the same time, the high cost of commercial culture media and the low yield of biological products determine the high cost of cell culture, which ultimately leads to high commercial production costs and high prices for biological products. In addition, due to the long production cycle of perfusion culture, there are high challenges to the quality stability of products during the production cycle. Therefore, developing a low-cost, simple to operate, high-yield culture medium with stable quality during the production cycle can reduce the overall price, ensure product quality, and benefit mankind. Summary of the invention
[0006] Problem that the invention aims to solve
[0007] In view of the problems existing in the prior art, for example, a common development method is to mix the basal medium and feed medium used in fed-batch culture in a certain proportion as a perfusion medium, and the development process lacks exploratory nature; in actual use, the preparation is not only complicated, but also not conducive to scale-up production. The present invention provides a culture medium for mammalian CHO cell culture and its application.
[0008] Solutions for solving problems
[0009] In view of the above problems existing in the prior art, the inventors conducted in-depth research and developed a culture medium suitable for perfusion culture based on the basic culture medium used in fed-batch culture through component optimization. The culture medium has a simple preparation and a clear chemical composition.
[0010] The technical solution of the present invention is as follows:
[0011] [1]. A culture medium for CHO cell culture, wherein the culture medium for CHO cell culture is a culture medium with a clear chemical composition;
[0012] The culture medium contains metal compounds, sugars, vitamins, amino acids, nucleosides / nucleoside compounds, fatty acids and other ingredients;
[0013] The metal compound includes: aluminum trichloride hexahydrate, ammonium metavanadate, barium acetate, calcium chloride, chromium (III) chloride hexahydrate, cobalt (II) chloride hexahydrate, copper sulfate pentahydrate, cyanocobalamin, manganese sulfate monohydrate, nickel (II) sulfate hexahydrate, potassium bromide, potassium chloride, potassium iodide, rubidium chloride, sodium chloride, sodium fluoride, sodium metasilicate nonahydrate, sodium phosphate monobasic, sodium pyruvate, tin (II) chloride dihydrate, zinc sulfate heptahydrate, zirconium oxychloride octahydrate and ammonium ferric citrate;
[0014] The sugars include glucose; the vitamins include folic acid, nicotinamide, vitamin C, inositol, pyridoxine hydrochloride, riboflavin and α-tocopherol acetate;
[0015] The amino acids include: L-arginine, L-asparagine monohydrate, L-aspartic acid, L-cysteine monohydrochloride monohydrate, L-cystine dihydrochloride, L-glutamic acid, L-histidine, L-isoleucine, L-leucine, L-lysine monohydrochloride, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine disodium salt and L-valine;
[0016] The nucleosides / nucleoside compounds include thymidine, hypoxanthine monosodium salt, cytosine, guanine, thymine, adenine, deoxycytidine 5'-monophosphate, 5'-adenosine monophosphate monohydrate and 2'-deoxyguanosine monohydrate;
[0017] The fatty acids include: arachidonic acid, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitic acid and stearic acid;
[0018] The other ingredients include: choline chloride, dextran sulfate sodium salt, ethanolamine hydrochloride and 1,4-butanediamine dihydrochloride.
[0019] [2] The medium for culturing CHO cells according to [1], wherein the metal compounds contained in the medium include: 0.02-0.08 mg / L aluminum chloride hexahydrate, 0.0005-0.0045 mg / L ammonium metavanadate, 0.05-0.15 mg / L barium acetate, 500-1500 mg / L calcium chloride, 0.002-0.006 mg / L chromium (III) chloride hexahydrate, 0.05-1.05 mg / L cobalt (II) chloride hexahydrate, 0.5-1.5 mg / L copper sulfate pentahydrate, 10.00-20.00 mg / L cyanocobalamin, 0.025-0.08 mg / L manganese sulfate monohydrate, 0.005-0.02 mg / L nickel sulfate (I I) Hexahydrate, 0.003-0.02 mg / L potassium bromide, 2000-4500 mg / L potassium chloride, 0.053-1.68 mg / L potassium iodide, 0.08-0.85 mg / L rubidium chloride, 3000-7000 mg / L sodium chloride, 0.02-0.18 mg / L sodium fluoride, 3.0-9.5 mg / L sodium metasilicate nonahydrate, 145-1200 mg / L of sodium phosphate monobasic, 360-1050 mg / L of sodium pyruvate, 0.0004-0.0028 mg / L of tin (II) chloride dihydrate, 25.5-80.0 mg / L of zinc sulfate heptahydrate, 0.05-0.30 mg / L of zirconium oxychloride octahydrate, and 20-90 mg / L of ammonium ferric citrate;
[0020] Preferably, the present invention comprises: 0.03-0.07 mg / L aluminum chloride hexahydrate, 0.001-0.003 mg / L ammonium metavanadate, 0.08-0.12 mg / L barium acetate, 700-1300 mg / L calcium chloride, 0.0035-0.0045 mg / L chromium (III) chloride hexahydrate, 0.3-0.7 mg / L cobalt (II) chloride hexahydrate, 0.35-1.25 mg / L copper sulfate pentahydrate, 12.00-17.00 mg / L cyanocobalamin, 0.03-0.075 mg / L manganese sulfate monohydrate, 0.008-0.175 mg / L nickel (II) sulfate hexahydrate, 0.008-0.012 mg / L g / L potassium bromide, 2300-4000 mg / L potassium chloride, 0.082-1.23 mg / L potassium iodide, 0.30-0.75 mg / L rubidium chloride, 4500-6400 mg / L sodium chloride, 0.05-0.11 mg / L sodium fluoride, 4.0-8.5 mg / L sodium metasilicate nonahydrate, 200-500 mg / L sodium phosphate monobasic, 450-1000 mg / L sodium pyruvate, 0.0006-0.0016 mg / L tin (II) chloride dihydrate, 35.0-60.0 mg / L zinc sulfate heptahydrate, 0.10-0.25 mg / L zirconium oxychloride octahydrate, and 20-60 mg / L ammonium ferric citrate;
[0021] More preferably, the ingredients include: 0.05 mg / L aluminum chloride hexahydrate, 0.002 mg / L ammonium metavanadate, 0.1 mg / L barium acetate, 1000 mg / L calcium chloride, 0.005 mg / L chromium (III) chloride hexahydrate, 0.5 mg / L cobalt (II) chloride hexahydrate, 1 mg / L copper sulfate pentahydrate, 15.00 mg / L cyanocobalamin, 0.05 mg / L manganese sulfate monohydrate, 0.01 mg / L nickel (II) sulfate hexahydrate, 0.01 mg / L Potassium bromide, 3000 mg / L potassium chloride, 1 mg / L potassium iodide, 0.5 mg / L rubidium chloride, 5900 mg / L sodium chloride, 0.1 mg / L sodium fluoride, 5.6 mg / L sodium metasilicate nonahydrate, 350 mg / L sodium phosphate monobasic, 800 mg / L sodium pyruvate, 0.001 mg / L tin (II) chloride dihydrate, 50.2 mg / L zinc sulfate heptahydrate, 0.15 mg / L zirconium oxychloride octahydrate and 50.00 mg / L ammonium ferric citrate.
[0022] [3] The medium for culturing CHO cells according to [1] or [2], wherein the vitamins contained in the medium include: 20-70 mg / L of folic acid, 15-80 mg / L of nicotinamide, 0.05-1.20 mg / L of vitamin C, 100-170 mg / L of inositol, 3.0-25.0 mg / L of pyridoxine hydrochloride, 0.5-5.6 mg / L of riboflavin and 0.025-0.095 mg / L of α-tocopherol acetate;
[0023] Preferably, it comprises: 20-50 mg / L of folic acid, 30-75 mg / L of nicotinamide, 0.5-1.0 mg / L of vitamin C, 120-160 mg / L of inositol, 8.0-12.0 mg / L of pyridoxine hydrochloride, 1.25-3.50 mg / L of riboflavin and 0.04-0.07 mg / L of α-tocopherol acetate;
[0024] More preferably, it comprises: 30 mg / L folic acid, 50 mg / L nicotinamide, 0.8 mg / L vitamin C, 150 mg / L inositol, 19 mg / L pyridoxine hydrochloride, 2 mg / L riboflavin and 0.056 mg / L α-tocopherol acetate.
[0025] [4] The medium for culturing CHO cells according to any one of [1] to [3], wherein the amino acids contained in the medium include: 500-1000 mg / L of L-arginine, 900-2500 mg / L of L-asparagine monohydrate, 500-1500 mg / L of L-aspartic acid, 50.0-500 mg / L of L-cysteine monohydrochloride monohydrate, 100-600 mg / L of L-cystine dihydrochloride, 200-1200 mg / L of L-glutamic acid, 500-1500 mg / L of L-histidine, 500-15 100-1800 mg / L of L-isoleucine, 500-1800 mg / L of L-leucine, 800-2000 mg / L of L-lysine monohydrochloride, 100-700 mg / L of L-methionine, 200-500 mg / L of L-phenylalanine, 150-1000 mg / L of L-proline, 500-1500 mg / L of L-serine, 400-1200 mg / L of L-threonine, 200-1000 mg / L of L-tryptophan, 225-1350 mg / L of L-tyrosine disodium salt and 100-300 mg / L of L-valine;
[0026] Preferably, the amino acid comprises 500-800 mg / L of L-arginine, 1000-2000 mg / L of L-asparagine monohydrate, 700-1000 mg / L of L-aspartic acid, 100-250 mg / L of L-cysteine monohydrochloride monohydrate, 100-400 mg / L of L-cystine dihydrochloride, 400-1000 mg / L of L-glutamic acid, 700-1100 mg / L of L-histidine, 600-1300 mg / L of L-isoleucine, 900-1600 mg / L of mg / L of L-leucine, 1000-1600 mg / L of L-lysine monohydrochloride, 300-600 mg / L of L-methionine, 250-400 mg / L of L-phenylalanine, 300-900 mg / L of L-proline, 700-1000 mg / L of L-serine, 650-900 mg / L of L-threonine, 400-950 mg / L of L-tryptophan, 500-900 mg / L of L-tyrosine disodium salt and 150-275 mg / L of L-valine;
[0027] More preferably, the composition comprises 600 mg / L of L-arginine, 1800 mg / L of L-asparagine monohydrate, 800 mg / L of L-aspartic acid, 200 mg / L of L-cysteine monohydrochloride monohydrate, 300 mg / L of L-cystine dihydrochloride, 500 mg / L of L-glutamic acid, 800 mg / L of L-histidine, 700 mg / L of L-isoleucine, 1500 mg / L of g / L of L-leucine, 1500 mg / L of L-lysine monohydrochloride, 500 mg / L of L-methionine, 300 mg / L of L-phenylalanine, 600 mg / L of L-proline, 800 mg / L of L-serine, 800 mg / L of L-threonine, 500 mg / L of L-tryptophan, 700 mg / L of L-tyrosine disodium salt and 200 mg / L of L-valine.
[0028] [5] The culture medium for culturing CHO cells according to any one of [1] to [4], wherein the nucleosides / nucleoside compounds contained in the culture medium include: 0.05-0.75 mg / L thymidine, 5.00-11.0 mg / L hypoxanthine monosodium salt, 1.25-9.5 mg / L cytosine, 2.5-9.0 mg / L guanine, 1.3-8.0 mg / L thymine, 0.5-8.5 mg / L adenine, 1.0-12 mg / L deoxycytidine 5'-monophosphate, 1.5-6.5 mg / L adenosine 5'-monophosphate monohydrate, and 2.00-8.00 mg / L 2'-deoxyguanosine monohydrate;
[0029] Preferably, the present invention comprises 0.10-0.55 mg / L of thymidine, 8.0-10.0 mg / L of hypoxanthine monosodium salt, 3.5-5.5 mg / L of cytosine, 3.0-4.5 mg / L of guanine, 2.5-6.0 mg / L of thymine, 1.0-6.0 mg / L of adenine, 3.0-7.0 mg / L of deoxycytidine 5'-monophosphate, 2.0-5.0 mg / L of adenosine 5'-monophosphate monohydrate and 2.0-6.0 mg / L of 2'-deoxyguanosine monohydrate;
[0030] More preferably, it comprises 0.2 mg / L thymidine, 10 mg / L hypoxanthine monosodium salt, 4 mg / L cytosine, 4 mg / L guanine, 4 mg / L thymine, 4 mg / L adenine, 4 mg / L deoxycytidine 5'-monophosphate, 4 mg / L adenosine 5'-monophosphate monohydrate and 4 mg / L 2'-deoxyguanosine monohydrate;
[0031] The fatty acids contained in the culture medium include: 0.0005-0.0030 mg / L arachidonic acid, 0.0020-0.10 mg / L linoleic acid, 0.0035-0.016 mg / L linolenic acid, 0.0028-0.035 mg / L myristic acid, 0.0045-0.018 mg / L oleic acid, 0.0045-0.020 mg / L palmitic acid and 0.005-0.012 mg / L stearic acid;
[0032] Preferably, it comprises 0.0010-0.0020 mg / L of arachidonic acid, 0.0035-0.10 mg / L of linoleic acid, 0.0055-0.009 mg / L of linolenic acid, 0.004-0.01 mg / L of myristic acid, 0.0065-0.010 mg / L of oleic acid, 0.005-0.015 mg / L of palmitic acid and 0.006-0.0012 mg / L of stearic acid;
[0033] More preferably, it comprises 0.0016 mg / L arachidonic acid, 0.008 mg / L linoleic acid, 0.008 mg / L linolenic acid, 0.008 mg / L myristic acid, 0.008 mg / L oleic acid, 0.008 mg / L palmitic acid and 0.008 mg / L stearic acid;
[0034] Other substances contained in the culture medium include: 100-300 mg / L of choline chloride, 20-70 mg / L of dextran sulfate sodium salt, 70-130 mg / L of ethanolamine hydrochloride and 0.06-1.1 mg / L of 1,4-butanediamine dihydrochloride;
[0035] Preferably, it comprises 150-250 mg / L of choline chloride, 40-70 mg / L of dextran sulfate sodium salt, 80-110 mg / L of ethanolamine hydrochloride and 0.4-0.9 mg / L of 1,4-butanediamine dihydrochloride;
[0036] More preferably, it comprises 200 mg / L of choline chloride, 60 mg / L of dextran sulfate sodium salt, 100 mg / L of ethanolamine hydrochloride and 0.5 mg / L of 1,4-butanediamine dihydrochloride;
[0037] The sugars contained in the culture medium include 5000-15000 mg / L of glucose, preferably 8000-11000 mg / L of glucose, and more preferably 10000 mg / L of glucose.
[0038] [6] The medium for culturing CHO cells according to any one of [1] to [5], wherein the medium further comprises a buffer substance and an anti-shear substance;
[0039] Preferably, the buffer substance comprises sodium bicarbonate, and the anti-shear substance comprises Pluronic F68;
[0040] Optionally, the content of sodium bicarbonate contained in the culture medium is 1000-3700 mg / L, preferably 1500-3500 mg / L, more preferably 2000 mg / L;
[0041] Optionally, the content of PluronicF68 contained in the culture medium is 1250-3600 mg / L, preferably 1600-2500 mg / L, and more preferably 2000 mg / L.
[0042] [7]. A method for culturing CHO cells, the method comprising the following steps:
[0043] (1) Cell recovery of CHO cells;
[0044] (2) performing seed expansion culture on the cells revived in step (1);
[0045] (3) First stage culture: according to the initial inoculation density (1.1±0.3)×10 6 The CHO cells obtained by seed expansion culture in step (2) were inoculated into the seed culture medium for culture at a temperature of 36.5±0.5°C and a stirring speed of 180-220 r / min. On the second day of culture, perfusion culture with the seed culture medium was started until the viable cell density reached 20.0×10 6 / mL or more, enter the second stage of cultivation;
[0046] (4) Second stage culture: perfusion culture using the culture medium described in any one of [1-6], when the viable cell density is greater than 60.0×10 6 / mL, cool to 33-35℃, adjust the speed to 230-280r / min, and maintain the viable cell density at 100.0×10 6 Pieces / mL;
[0047] Preferably, the seed culture medium is CD CHO medium;
[0048] Optionally, during the culture process, the dissolved oxygen is controlled to 20% to 80%, preferably 50%; the pH value is controlled to 7.00±0.35;
[0049] Optionally, the first stage culture time is 4 to 6 days in total.
[0050] [8] The method for culturing CHO cells according to [7], wherein:
[0051] The specific operation of cell recovery in step (1) is as follows: taking out the seed cells from the -80°C refrigerator for recovery, inoculating them into CD CHO culture medium, and culturing them at 36.5±0.5°C, 6.0±1.0% CO2, and 130±10 r / min for 2 to 4 days;
[0052] The specific operation of the seed expansion culture in step (2) is: the revived cells obtained in step (1) are cultured at a rate of 0.3 to 0.7×10 6 Inoculate the cells at a density of 100 cells / mL into a shake flask containing CD CHO medium, and culture at 36.5±0.5°C, 6.0±1.0% CO2, and 130±10 r / min for 2 to 4 days. Follow this step to gradually expand the seed cells in a 250-2000 mL shake flask;
[0053] In the step (3), starting from the second day of culture, the seed culture medium is perfused at a rate of 0.5 VVD, and then the perfusion rate is increased by 0.5 VVD every day to no more than 2.0 VVD;
[0054] In the step (4), the culture medium described in any one of [1] to [6] is used for perfusion culture at a rate of 0.5 VVD; when the glucose concentration in the reaction system is lower than 2.00 g / L, glucose is added to maintain the glucose concentration in the reaction system not lower than 2.00 g / L; when the glucose concentration is higher than 3.00 g / L, the amount of glucose added is gradually reduced until the addition stops; optionally, when the glucose concentration is lower than 2.00 g / L, the amount of glucose added is increased in units of 1.00 g / L / day until the concentration is no longer lower than 2.00 g / L; optionally, when the glucose concentration is greater than 3.00 g / L, the amount of glucose added is reduced in units of 1.00 g / L / day.
[0055] [9]. The method for culturing CHO cells according to [7] or [8], wherein the CHO cells are CHO cells encoding exogenous proteins; preferably, the CHO cells are CHO-K1, CHO-S, CHO-K1SV, CHO-GS or CHO-DG44, and the exogenous protein is an antibody; more preferably, the exogenous protein is a monoclonal antibody or a bispecific antibody.
[0056]
[10] . Use of the culture medium for CHO cell culture described in any one of [1] to [6] for CHO cells expressing exogenous proteins; preferably, the CHO cells are CHO-K1, CHO-S, CHO-K1SV, CHO-GS or CHO-DG44, and the exogenous protein is an antibody; more preferably, the exogenous protein is a monoclonal antibody or a bispecific antibody.
[0057] Effects of the Invention
[0058] It can be seen from the technical solution of the present invention that the technical solution of the present invention has the following beneficial effects compared with the prior art:
[0059] (1) The culture medium provided by the present invention has clear chemical composition and simple preparation, which is conducive to the production and subculture of CHO cells, the efficient expression of protein products and commercial scale-up production, and saves the production cost of protein products.
[0060] (2) The culture medium provided by the present invention is suitable for the culture of CHO cell line cells, such as CHO-K1, CHO-S, CHO-K1SV, etc., and has a wide range of applications and high universality.
[0061] (3) The culture medium provided by the present invention can maintain a good cell viability and high expression ability during the fermentation cycle during the actual perfusion culture process, and is simple to operate. It not only meets the cycle requirements of perfusion culture, but also meets the high production capacity requirements of the current bio-industry. The maintenance of high cell viability and the simple preparation of the culture medium are more conducive to commercial scale-up production.
[0062] (4) The culture medium provided by the present invention is of guaranteed quality in culturing biological products. The cell metabolism and product quality are stable during the perfusion fermentation cycle. The output material has high purity and few charge variants, which is beneficial to the development of the downstream biopharmaceutical sector and also saves costs to a certain extent. BRIEF DESCRIPTION OF THE DRAWINGS
[0063] Figure 1 A curve chart showing the change of live cell density over time in the experimental group and the control group in the embodiment.
[0064] Figure 2 A curve chart showing the change of cell viability over time in the experimental group and the control group in the embodiment is shown.
[0065] Figure 3 A curve chart showing the change of glucose concentration over time in the experimental group and the control group in the embodiment.
[0066] Figure 4 The NH4 + Plot of concentration versus time.
[0067] Figure 5 A curve chart showing the cumulative yield changes over time in the experimental group and the control group in the embodiment is shown.
[0068] Figure 6 A curve chart showing the change of specific productivity over time in the experimental group and the control group in the example.
[0069] Figure 7 The main component ratios measured by size exclusion chromatography in the experimental group and the control group in the embodiment are shown.
[0070] Figure 8 The main component ratios measured by CE-SDS in the experimental group and the control group in the embodiment are shown.
[0071] Fig. 9 The ratio of acidic charge variants in the experimental group and the control group in the examples is shown. DETAILED DESCRIPTION
[0072] Various exemplary embodiments, features and aspects of the present invention will be described in detail below. The word "exemplary" used here means "used as an example, embodiment or illustrative". Any embodiment described here as "exemplary" is not necessarily interpreted as being superior or better than other embodiments.
[0073] In addition, in order to better illustrate the present invention, numerous specific details are provided in the following specific embodiments. It should be understood by those skilled in the art that the present invention can be implemented without certain specific details. In other examples, methods, means, equipment and steps well known to those skilled in the art are not described in detail in order to highlight the subject matter of the present invention.
[0074] definition
[0075] When used in conjunction with the term "comprising" in the claims and / or the specification, the word "a" or "an" can mean "one", but can also mean "one or more", "at least one" and "one or more than one".
[0076] As used in the claims and description, the words "comprising," "having," "including," or "containing" are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[0077] As used herein, the term "about" means that a value includes the standard deviation of error of the device or method used to determine the value. Exemplarily, the standard deviation is generally within the range of 20-30% of the original value.
[0078] Although the disclosure supports the definition of the term "or" as only alternatives and "and / or", the term "or" in the claims means "and / or" unless it is explicitly stated that it is only alternatives or the alternatives are mutually exclusive. In this specification, when the term "and / or" is used to connect two or more options, it should be understood to mean any one of the options or any two or more of the options.
[0079] When used in the claims or specification, a selected / optional / preferred "numerical range" includes both the numerical endpoints at both ends of the range and all natural numbers covered between the numerical endpoints relative to the aforementioned numerical endpoints.
[0080] In the present invention, the term "CHO cells" refers to Chinese hamster ovary (CHO) cells, which are the most widely used mammalian cell expression system for the production of recombinant pharmaceutical proteins and are also a hot topic in bioprocess and drug development research. The culture process of CHO cells is very robust and can produce a variety of recombinant glycoproteins at high levels on a large scale.
[0081] In the present invention, the term "inoculation density" refers to the initial cell density for inoculating a shake flask or a bioreactor.
[0082] In the present invention, the term "cell culture" refers to a method of simulating the in vivo environment (sterility, suitable temperature, pH and certain nutritional conditions, etc.) in vitro to enable cells to survive, grow, reproduce and maintain their main structures and functions.
[0083] In the present invention, the term "perfusion cell culture" or "perfusion culture" refers to adding cells and culture medium into a reactor, continuously removing part of the conditioned medium during cell growth and product formation, and continuously perfusing new culture medium.
[0084] In the present invention, the term "fed-batch culture" refers to the continuous or intermittent addition of a specific fed-batch culture medium into the reactor to supplement new nutrients according to the metabolic needs of the cells during the culture process.
[0085] In the present invention, the term "bioreactor" refers to a container for culturing cells, which utilizes the biological functions of enzymes or organisms (such as microorganisms) to perform biochemical reactions in vitro, and is a biological function simulator.
[0086] As used herein, the term "dissolved oxygen" or "DO" refers to the percentage of dissolved oxygen present in a given liquid (such as a cell culture medium) based on saturated air.
[0087] In the present invention, the term "cell bleeding" refers to the removal of a portion of the culture medium from the tank during the perfusion culture process to determine the cell growth rate to maintain a high cell activity and prevent the cell retention module of the perfusion system from being blocked.
[0088] In the present invention, the term "viable cell density" refers to the number of viable cells per unit area or volume, and is used to reflect the cell growth status.
[0089] In the present invention, the term "cell viability" refers to the percentage of live cells in the total cell population.
[0090] In the present invention, the term "cumulative yield" refers to the total yield in one culture cycle.
[0091] In the present invention, the term "perfusion flow rate" is a key parameter for process performance, which is usually defined as the perfusion rate (tank volume per day, VVD, L / (L·day)) or the cell specific perfusion rate (cell specific perfusion rate, CSPR, nL / cell / day).
[0092] In the present invention, the term "VCD (viable cell density)" or "viable cell density" refers to the number of viable cells contained in a certain volume of culture medium, and is expressed in units of "cells / mL" or "cells / mL". In the present invention, the term "VIB (Viability)" or "cell viability" refers to the ratio of the total number of viable cells contained in a certain volume of culture medium to the total number of cells, and is expressed in units of "%".
[0093] In the present invention, the term "antibody expression level" refers to the total amount of antibodies produced in a certain volume of cell culture, and is expressed in the unit of "g / L".
[0094] In the present invention, the term "specific productivity" refers to the growth rate and productivity calculated in picograms of protein produced per cell per day, and the calculation is shown as follows:
[0095] Specific productivity = antibody production / cumulative viable cell density;
[0096] The calculation formula for "IVCD (integral viable cell density)" or "cumulative viable cell density" is as follows:
[0097]
[0098] Where t is the culture time (unit: day), VCD is the viable cell density (unit: cell / mL), VCD t is the viable cell density on the tth day of culture, V is the culture volume (unit: mL), V t is the culture volume on the tth day of culture, and V0 is the initial culture volume.
[0099] In the present invention, the term "size exclusion chromatography" is an analytical method that utilizes the uniqueness of a porous gel stationary phase to separate solutes based on the relative relationship between the pore size of the gel pores and the coil size of the polymer sample molecule.
[0100] In the present invention, the term "CE-SDS" refers to the sodium dodecyl sulfate capillary electrophoresis (CE-SDS) ultraviolet detection method, which quantitatively determines the purity of recombinant monoclonal antibody products according to the molecular weight under reducing and non-reducing conditions by capillary electrophoresis.
[0101] In the present invention, the term "main component" refers to the target product, and the higher the purity, the more target product is obtained.
[0102] The "charge variants" described in the present invention are called charge variants because the protein products undergo post-translational modification and degradation events in cells, resulting in heterogeneity in biophysical properties and differences in charges.
[0103] As described in the present invention, "acidic charge variants" are charge variants that are earlier or later than the main peak in different analytical methods. There are many reasons for the formation of acidic charge variants, among which there may be modifications that affect the biological activity of the product. Therefore, the level of acidic charge variants is generally used as an indicator of the quality of the antibody product.
[0104] First aspect
[0105] The first aspect of the present invention provides a culture medium for CHO cell culture, wherein the culture medium comprises metal compounds, sugars, vitamins, amino acids, nucleosides / nucleoside compounds, fatty acids and other components.
[0106] Specifically, the culture medium provided by the present invention contains carbon sources, nitrogen sources, amino acids, vitamins, metal compounds, nucleosides / nucleoside compounds, fatty acids, buffers, anti-shear substances, trace elements and other nutrients to promote CHO cell growth, maintenance and product expression.
[0107] In the present invention, carbon source, as the most important energy source, provides the skeleton of required energy and product synthesis for biosynthesis. Different carbon source forms have different effects. Commonly used ones include glucose, galactose, mannose, fucose, sodium pyruvate, maltose, isomaltose, fructose, sucrose, arabinose, oligofructose, oligoxylose, etc. Nitrogen source is the main tissue part that promotes protein synthesis of organisms. Commonly used nitrogen sources include various ammonium salts, nitrates, peptones, fish meal, etc., and the nitrates include sodium nitrate, potassium nitrate, magnesium nitrate, aluminum nitrate, zinc nitrate, iron nitrate, copper nitrate or manganese nitrate, and the ammonium salts include ammonium chloride, ammonium sulfate or ammonium nitrate. In some specific embodiments, the carbon source includes glucose, preferably D-glucose.
[0108] In the present invention, amino acids are an important basis for cell growth and metabolism, are the basic units that constitute proteins, and are also energy sources and signal molecules. Amino acids with different component contents directly affect cell growth, maintenance and expression of protein products, and even affect the quality attributes of products. Commonly used amino acids are divided into essential amino acids and non-essential amino acids. Essential amino acids cannot be synthesized by cells themselves and must be provided by culture medium. Essential amino acids include L-glutamine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, and L-valine. Among them, L-glutamine is an essential amino acid for cells to synthesize nucleic acids and proteins. Different CHO cell types have different requirements for amino acids. In some specific embodiments, the amino acid includes L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-alanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine and L-valine. Optionally, the amino acid is added to the culture medium in the form of a monohydrate, a hydrochloride and / or a sodium salt.
[0109] In the present invention, vitamins provide a large amount of coenzyme factors for the body and play an important role in the metabolic process; most vitamins are sensitive to strong light and heat and are easily oxidized. In some specific embodiments, the vitamins include at least one of folic acid, nicotinamide, vitamin C, inositol, pyridoxine hydrochloride, riboflavin and α-tocopherol acetate.
[0110] In the present invention, the metal compound in the culture medium dissolves in water to produce metal ions, which can participate in cell division and play an important role in maintaining cell structure and strengthening lipoprotein membranes; metal ions also directly affect the structure of ribosomes, thereby affecting the normal synthesis process of proteins. In some specific embodiments, the metal ions include aluminum ions, iron ions, vanadium ions, divalent cobalt ions, trivalent cobalt ions, barium ions, calcium ions, trivalent chromium ions, copper ions, potassium ions, rubidium ions, sodium ions, divalent tin ions, zinc ions, zirconium ions, and trivalent iron ions. In some specific embodiments, the metal compound includes aluminum trichloride hexahydrate, ammonium metavanadate, barium acetate, calcium chloride, chromium (III) chloride hexahydrate, cobalt (II) chloride hexahydrate, copper sulfate pentahydrate, cyanocobalamin, manganese sulfate monohydrate, nickel (II) sulfate hexahydrate, potassium bromide, potassium chloride, potassium iodide, rubidium chloride, sodium chloride, sodium fluoride, sodium metasilicate nonahydrate, sodium phosphate monobasic (i.e., NaH2PO4), sodium pyruvate, tin (II) chloride dihydrate, zinc sulfate heptahydrate, zirconium oxychloride octahydrate and ammonium ferric citrate.
[0111] In the present invention, lipid substances are the main components of cell membranes, which provide energy and serve signal pathways in cells. Commonly used ones include fatty acids, phospholipids (such as ethanolamine) and cholesterol. Exemplarily, the fatty acids include arachidonic acid, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitic acid and stearic acid.
[0112] In the present invention, nucleosides / nucleoside compounds provide raw materials for cell division and DNA replication, so that cell DNA replication proceeds smoothly, thereby ensuring normal cell division. Exemplarily, the nucleosides / nucleoside compounds include thymidine, hypoxanthine monosodium salt, cytosine, guanine, thymine, adenine, deoxycytidine 5'-monophosphate, 5'-monophosphate adenosine monohydrate and 2'-deoxyguanosine monohydrate.
[0113] Furthermore, the culture medium also contains other components, including some energy substances, hormones and serum substitutes, which play an important role in maintaining normal cell growth and expression. In some specific embodiments, the other components include choline chloride, dextran sulfate sodium salt, ethanolamine hydrochloride and 1,4-butanediamine dihydrochloride.
[0114] In the present invention, the buffer substance in the culture medium can regulate the permeability of the cell membrane, maintain normal osmotic pressure and acid-base balance inside and outside the cell, and promote cell growth. In some embodiments of the present invention, the buffer substance includes sodium bicarbonate.
[0115] In the present invention, the anti-shear substance in the culture medium can protect cells from the damage of shear force during the culture process, and the anti-shear substance includes a non-ionic surfactant, etc. In some specific embodiments, the anti-shear substance is Pluronic F68.
[0116] Second aspect
[0117] A second aspect of the present invention provides a method for culturing CHO cells, the method comprising the following steps:
[0118] The CHO cells were revived by taking out the seed cells from the -80°C refrigerator for resuscitation, inoculating them into CD CHO culture medium, and culturing them at 36.5±0.5°C, 6.0±1.0% CO2, and 130±10 r / min for 2 to 4 days.
[0119] Furthermore, the cells revived in the above step are subjected to seed expansion culture. The specific operation is: the revived cells obtained in the above step are cultured at a rate of 0.3-0.7×10 6The cells were inoculated into a shake flask containing CD CHO medium at a density of 100 cells / mL, cultured at 36.5±0.5°C, 6.0±1.0% CO2, and 130±10 r / min for 2 to 4 days, and then expanded step by step until the number of cells meets the perfusion inoculation requirements of a 2L reactor. For example, in a reactor with a working volume of 1.0 to 1.3 L, the cell concentration can reach 0.8 to 1.4×10 6 / mL, preferably, in a reactor with a working volume of 1.1L, the cell concentration can reach 1.1×10 6 In some specific embodiments, the stepwise expansion culture is to expand and culture the seed cells in 250 mL, 500 mL, 1000 mL and 2000 mL shaking flasks in sequence.
[0120] Furthermore, after the seed expansion culture, the first stage culture was carried out, and the specific steps were as follows: according to the initial inoculation density (1.1±0.3)×10 6 The CHO cells obtained by seed expansion culture in step (2) were inoculated into the seed culture medium for culture at a temperature of 36.5±0.5°C and a stirring speed of 180-220 r / min. On the second day of culture, perfusion culture with the seed culture medium was started until the viable cell density reached 20.0×10 6 / mL or more, enter the second stage of culture; in some embodiments, the seed culture medium is used for perfusion culture at a rate of 0.5VVD starting from the second day of culture, and then the perfusion rate is increased by 0.5VVD every day to no more than 2.0VVD (i.e., for example, perfusion culture is performed at rates of 0.5VVD, 1.0VVD, 1.5VVD, and 2.0VVD, respectively); in some optional embodiments, the first stage of culture time is 4 to 6 days in total, preferably 6 days.
[0121] Furthermore, after the first stage of culture, the second stage of culture is carried out, and the specific steps are: perfusion culture with the above-mentioned culture medium, when the viable cell density is greater than 60.0×10 6 / mL, cool to 33-35℃, adjust the speed to 230-280r / min, and maintain the viable cell density at 100.0×10 6 / mL; in some embodiments, the above-mentioned culture medium is used for perfusion culture at a rate of 0.5VVD; when the glucose concentration in the reaction system is lower than 2.00g / L, glucose is added to maintain the glucose concentration in the reaction system not lower than 2.00g / L, and when the glucose concentration is higher than 3.00g / L, the amount of glucose added is gradually reduced until the addition stops; in some optional embodiments, when the glucose concentration in the tank is lower than 2.00g / L, glucose addition is started, and the initial glucose addition amount is 1.00g / L / day, and then the glucose addition amount is increased by a gradient of 1.00g / L / day until the glucose concentration in the tank is no longer lower than 2.00g / L; when the glucose concentration in the tank is greater than 3.00g / L, the glucose addition amount is gradually reduced by a gradient of 1.00g / L / day.
[0122] In some preferred embodiments, the seed culture medium is CD CHO medium.
[0123] In some optional embodiments, during the culture process, the dissolved oxygen is controlled to be 20% to 80%, preferably 50%; and the pH value is controlled to be 7.00±0.35.
[0124] In some embodiments, the CHO cell is a CHO cell containing an encoded exogenous protein; preferably, the CHO cell is CHO-K1, CHO-S, CHO-K1SV, CHO-GS or CHO-DG44, and the exogenous protein is an antibody; more preferably, the exogenous protein is a monoclonal antibody or a bispecific antibody.
[0125] The third aspect
[0126] The third aspect of the present invention provides the use of the culture medium for CHO cell culture in the expression of foreign proteins by CHO cells.
[0127] In some preferred embodiments, the CHO cell is CHO-K1, CHO-S, CHO-K1SV, CHO-GS or CHO-DG44, and the exogenous protein is an antibody.
[0128] In some more preferred embodiments, the exogenous protein is a monoclonal antibody or a bispecific antibody.
[0129] Example
[0130] The embodiments of the present invention will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.
[0131] The key instruments, equipment, materials and consumables used in the embodiments of the present invention are shown in Tables 1 and 2 below.
[0132] Table 1. Key instruments and equipment used in the experiment
[0133] Device Name Origin and brand Cell Counter Beckman Coulter, USA Automatic biochemical analyzer Roche, Switzerland High performance liquid chromatography Agilent Biological Safety Cabinets Suzhou Sujing Antai Carbon dioxide shaker Kuhner, Switzerland Bioreactor Applikon, Netherlands My-control Applikon, Netherlands Centrifuge Hunan Xiangyi Centrifuge Thermo Fisher Scientific, USA Take over machine Terumo USA Tube Sealing Machine Startorius, Germany
[0134] Table 2. Experimental materials and key consumables
[0135]
[0136] Example 1: 2L reactor perfusion culture
[0137] Experimental materials: The CHO-K1SV GS-KO cell line, which was acclimated with CHO-K1 (ECACC) serum-free suspension, contained an electroporated plasmid and a gene sequence encoding an anti-VEGF monoclonal antibody (bevacizumab) and could express the corresponding antibody.
[0138] Perfusion medium: The present invention obtains the optimal content and the better content of each component of the perfusion medium through overall optimization. The detailed formula is shown in Table 3 below.
[0139] Table 3. Components and contents in perfusion medium
[0140]
[0141]
[0142]
[0143] The cell culture process mainly includes three steps: cell recovery, seed expansion and 2L reactor perfusion culture. CD CHO seed culture medium is used in both the cell recovery and seed expansion stages, and the perfusion culture medium with the optimal component content in the present invention or the control commercial perfusion culture medium is used in the 2L reactor perfusion culture stage.
[0144] The following cell culture process parameter settings are the optimal parameter conditions. In addition, each parameter condition has an acceptable range.
[0145] (1) Cell recovery: Take out a frozen cell from the -80℃ freezer and quickly place it in a water bath at 37.0±0.5℃ for no more than 2 minutes. Gently mix the cells after thawing in the water bath and transfer them to a centrifuge tube containing 8.5ml CD CHO seed medium. Centrifuge at 1000rpm for 5min, discard the supernatant, gently suspend the cell pellet with about 5ml CD CHO medium and transfer it to a shake flask containing 25ml CD CHO medium, and place it in a shaker at 36.5℃ (acceptable range is 36.0~37.0℃), 6.0% CO2 (acceptable range is 5.0%~7.0% CO2), 130r / min (acceptable range is 120~140r / min) and culture for 3 days (acceptable range is 2~4 days).
[0146] (2) Seed expansion: The cells revived in step (1) above were cultured at 0.5 × 10 6 / ml (the acceptable range is 0.3~0.7×10 6 The cells were inoculated into a new shake flask at a density of 1000 cells / ml and placed in a carbon dioxide shaker. The culture conditions were: 36.5°C (acceptable range: 36.0-37.0°C), 6.0% CO2 (acceptable range: 5.0%-7.0% CO2), 130r / min (acceptable range: 120-140r / min), and cultured for 3 days (acceptable range: 2-4 days). The seed was amplified using shake flasks of 250ml, 500ml, 1000ml and 2000ml specifications step by step, and the amplification volume was gradually increased until the number of cells in the shake flask met the inoculation requirements of the 2L reactor perfusion culture. The inoculation requirements of the 2L reactor perfusion culture are shown in step (3).
[0147] (3) 2 L reactor perfusion culture: The perfusion medium of the present invention and the perfusion medium purchased from Merck were used respectively. INV-PM perfusion culture medium was used for parallel experiments. Except for the perfusion culture medium, the other materials and process parameters were the same. The perfusion culture process is as follows:
[0148] The cells obtained by stepwise expansion in step (2) above were cultured at a rate of 1.1×10 6 / ml (acceptable range is 0.8~1.4×10 6The cells were inoculated at a density of 0.5VVD perfusion culture using CD CHO seed medium (cells / ml) in a 2L Applikon perfusion bioreactor controlled by my-control with a working volume of 1.1L. The culture medium used in the first stage was CD CHO seed medium, the culture temperature was 36.5°C (the acceptable range was 36.0-37.0°C), the initial stirring speed setting was 200r / min, the pH value was set to 7.00±0.30, ranging from 6.65 to 7.35; the dissolved oxygen was set to 50% (the acceptable range was 20% to 80%). On the second day after inoculation, CD CHO seed medium was used for perfusion culture at 0.5VVD, and then 0.5VVD was increased to 2.0VVD every day for 6 days (the acceptable range was 4-6 days). When the viable cell density reached 20.0×10 6 / ml, enter the second stage and start using perfusion medium at 2.0VVD perfusion culture. Set the pH value to 7.00±0.30, ranging from 6.65 to 7.35; DO to 50%, ranging from 20% to 80%; culture temperature to 36.5℃, ranging from 36.0 to 37.0℃. When VCD exceeds 60×10 6 / ml and cooled to 35℃. Adjust the speed to 250r / min (230~280r / min) according to the cell density. 6 When the viable cell density reached 100.0×10 / ml, cell bleeding was performed to maintain the viable cell density at 100.0×10 6 Pieces / ml.
[0149] During the perfusion culture stage using perfusion medium, glucose is added according to the daily test results of glucose concentration. When the glucose concentration is lower than 2.00g / L, glucose is automatically added at a rate of 1.00g / L / day. During the process of starting glucose addition, when the glucose concentration is lower than 2.00g / L, it is increased in units of 1.00g / L / day until the concentration is no longer lower than 2.00g / L; when the glucose concentration is higher than 3.00g / L, it is reduced in units of 1.00g / L / day until the glucose addition stops. Add defoamer according to the actual amount of foam, and the total amount cannot exceed 200ppm.
[0150] Samples were taken one hour after inoculation, and the daily sampling interval was controlled within 24 hours (acceptable range 20-28 hours). Cell density, viability, glucose concentration, lactic acid concentration, NH4 + In addition, the protein yield was determined, the specific productivity was calculated, and the proportion of the main components in the protein was determined by size exclusion chromatography and CE-SDS.
[0151] Experimental results: By monitoring the growth metabolism of cells, protein expression ability and quality indicators of the product, the present invention is comprehensively evaluated. Figures 1 to 9 , where the solid line is the performance of the perfusion culture medium of the present invention; the dotted line is the performance of the Merck The performance of INV-PM perfusion culture medium was defined as the control group.
[0152] Compared with control medium:
[0153] like Figure 1 As shown in the figure, the cells grew faster in the perfusion medium of the present invention in the early stage, and the maximum viable cell density was slightly higher, reaching 149.1×10 6 The cell density tended to be consistent in the later stage of culture, and the cell density on the day of culture termination (26th day) was 110.1×10 6 / ml, the control was 104.5×10 6 Pieces / ml.
[0154] like Figure 2 As shown, in the perfusion culture medium of the present invention, the cell viability was better maintained, and the cell viability on the 26th day was 94.2%, while that of the control was 93.0%.
[0155] In terms of glucose metabolism, cells cultured in the medium of the present invention have a high glucose utilization rate ( Figure 3 ); NH4 + The level was lower than that of the control group, and the cell culture microenvironment was relatively good ( Figure 4 ).
[0156] In terms of antibody expression capacity (i.e., protein production), cells cultured in the medium of the present invention have high antibody expression capacity ( Figure 5 ), the cumulative yield of the present invention is as high as 101.35g / L, the cumulative yield of the control is 79.14g / L, and the total yield is increased by 28% compared with Merck culture medium; and the specific cell productivity of the cell antibody cultured in the culture medium of the present invention is higher than that of the control group ( Figure 6 ).
[0157] like Figure 7 to Figure 9 As shown, the quality is relatively stable during the culture period, and the overall purity at different detection points is higher than that of Merck medium, and the acidic charge variant is lower than that of Merck medium.
[0158] Overall, it is shown that the culture medium of the present invention not only reduces the production cost, but also maintains good cell growth and viability, high antibody expression ability, and the quality of the protein product is stable during the production cycle. The product not only has high purity, but also has fewer charge variants that affect the biological activity of the product.
[0159] It should be noted that, although the technical solution of the present invention is introduced with specific examples, those skilled in the art will appreciate that the present invention should not be limited thereto.
[0160] The embodiments of the present invention have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The selection of terms used herein is intended to best explain the principles of the embodiments, practical applications, or technical improvements in the market, or to enable other persons of ordinary skill in the art to understand the embodiments disclosed herein.
Claims
1. A culture medium for CHO cell culture, characterized in that: The culture medium for CHO cell culture is a culture medium with clear chemical composition; The culture medium contains metal compounds, sugars, vitamins, amino acids, nucleosides / nucleoside compounds, fatty acids and other ingredients; The metal compound includes: aluminum trichloride hexahydrate, ammonium metavanadate, barium acetate, calcium chloride, chromium (III) chloride hexahydrate, cobalt (II) chloride hexahydrate, copper sulfate pentahydrate, cyanocobalamin, manganese sulfate monohydrate, nickel (II) sulfate hexahydrate, potassium bromide, potassium chloride, potassium iodide, rubidium chloride, sodium chloride, sodium fluoride, sodium metasilicate nonahydrate, sodium phosphate monobasic, sodium pyruvate, tin (II) chloride dihydrate, zinc sulfate heptahydrate, zirconium oxychloride octahydrate and ammonium ferric citrate; The sugars include glucose; the vitamins include folic acid, nicotinamide, vitamin C, inositol, pyridoxine hydrochloride, riboflavin and α-tocopherol acetate; The amino acids include: L-arginine, L-asparagine monohydrate, L-aspartic acid, L-cysteine monohydrochloride monohydrate, L-cystine dihydrochloride, L-glutamic acid, L-histidine, L-isoleucine, L-leucine, L-lysine monohydrochloride, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine disodium salt and L-valine; The nucleosides / nucleoside compounds include: thymidine, hypoxanthine monosodium salt, cytosine, guanine, thymine, adenine, deoxycytidine 5'-monophosphate, 5'-adenosine monophosphate monohydrate and 2'-deoxyguanosine monohydrate; The fatty acids include: arachidonic acid, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitic acid and stearic acid; The other ingredients include: choline chloride, dextran sulfate sodium salt, ethanolamine hydrochloride and 1,4-butanediamine dihydrochloride.
2. The culture medium for CHO cell culture according to claim 1, characterized in that The metal compounds contained in the culture medium include: 0.02-0.08 mg / L aluminum chloride hexahydrate, 0.0005-0.0045 mg / L ammonium metavanadate, 0.05-0.15 mg / L barium acetate, 500-1500 mg / L calcium chloride, 0.002-0.006 mg / L chromium (III) chloride hexahydrate, 0.05-1.05 mg / L cobalt (II) chloride hexahydrate, 0.5-1.5 mg / L copper sulfate pentahydrate, 10.00-20.00 mg / L cyanocobalamin, 0.025-0.08 mg / L manganese sulfate monohydrate, 0.005-0.02 mg / L nickel (II) sulfate hexahydrate, 0.003-0 0.02mg / L potassium bromide, 2000-4500mg / L potassium chloride, 0.053-1.68mg / L potassium iodide, 0.08-0.85mg / L rubidium chloride, 3000-7000mg / L sodium chloride, 0.02-0.18mg / L sodium fluoride, 3.0-9.5mg / L sodium metasilicate nonahydrate, 145-1200mg / L sodium phosphate monobasic, 360-1050mg / L sodium pyruvate, 0.0004-0.0028mg / L tin (II) chloride dihydrate, 25.5-80.0mg / L zinc sulfate heptahydrate, 0.05-0.30mg / L zirconium oxychloride octahydrate and 20-90mg / L ammonium ferric citrate; Preferably, the present invention comprises: 0.03-0.07 mg / L aluminum chloride hexahydrate, 0.001-0.003 mg / L ammonium metavanadate, 0.08-0.12 mg / L barium acetate, 700-1300 mg / L calcium chloride, 0.0035-0.0045 mg / L chromium (III) chloride hexahydrate, 0.3-0.7 mg / L cobalt (II) chloride hexahydrate, 0.35-1.25 mg / L copper sulfate pentahydrate, 12.00-17.00 mg / L cyanocobalamin, 0.03-0.075 mg / L manganese sulfate monohydrate, 0.008-0.175 mg / L nickel (II) sulfate hexahydrate, 0.008-0.012 mg / L g / L potassium bromide, 2300-4000 mg / L potassium chloride, 0.082-1.23 mg / L potassium iodide, 0.30-0.75 mg / L rubidium chloride, 4500-6400 mg / L sodium chloride, 0.05-0.11 mg / L sodium fluoride, 4.0-8.5 mg / L sodium metasilicate nonahydrate, 200-500 mg / L sodium phosphate monobasic, 450-1000 mg / L sodium pyruvate, 0.0006-0.0016 mg / L tin (II) chloride dihydrate, 35.0-60.0 mg / L zinc sulfate heptahydrate, 0.10-0.25 mg / L zirconium oxychloride octahydrate, and 20-60 mg / L ammonium ferric citrate; More preferably, the mixture includes: 0.05 mg / L aluminum chloride hexahydrate, 0.002 mg / L ammonium metavanadate, 0.1 mg / L barium acetate, 1000 mg / L calcium chloride, 0.005 mg / L chromium (III) chloride hexahydrate, 0.5 mg / L cobalt (II) chloride hexahydrate, 1 mg / L copper sulfate pentahydrate, 15.00 mg / L cyanocobalamin, 0.05 mg / L manganese sulfate monohydrate, 0.01 mg / L nickel (II) sulfate hexahydrate, 0.01 mg / L L of potassium bromide, 3000 mg / L of potassium chloride, 1 mg / L of potassium iodide, 0.5 mg / L of rubidium chloride, 5900 mg / L of sodium chloride, 0.1 mg / L of sodium fluoride, 5.6 mg / L of sodium metasilicate nonahydrate, 350 mg / L of sodium phosphate monobasic, 800 mg / L of sodium pyruvate, 0.001 mg / L of tin (II) chloride dihydrate, 50.2 mg / L of zinc sulfate heptahydrate, 0.15 mg / L of zirconium oxychloride octahydrate and 50.00 mg / L of ammonium ferric citrate.
3. The culture medium for CHO cell culture according to claim 1 or 2, characterized in that: The vitamins contained in the culture medium include: 20-70 mg / L of folic acid, 15-80 mg / L of nicotinamide, 0.05-1.20 mg / L of vitamin C, 100-170 mg / L of inositol, 3.0-25.0 mg / L of pyridoxine hydrochloride, 0.5-5.6 mg / L of riboflavin and 0.025-0.095 mg / L of α-tocopherol acetate; Preferably, it comprises: 20-50 mg / L of folic acid, 30-75 mg / L of nicotinamide, 0.5-1.0 mg / L of vitamin C, 120-160 mg / L of inositol, 8.0-12.0 mg / L of pyridoxine hydrochloride, 1.25-3.50 mg / L of riboflavin and 0.04-0.07 mg / L of α-tocopherol acetate; More preferably, it comprises: 30 mg / L folic acid, 50 mg / L nicotinamide, 0.8 mg / L vitamin C, 150 mg / L inositol, 19 mg / L pyridoxine hydrochloride, 2 mg / L riboflavin and 0.056 mg / L α-tocopherol acetate.
4. The culture medium for CHO cell culture according to any one of claims 1 to 3, characterized in that The amino acids contained in the culture medium include: 500-1000 mg / L of L-arginine, 900-2500 mg / L of L-asparagine monohydrate, 500-1500 mg / L of L-aspartic acid, 50.0-500 mg / L of L-cysteine monohydrochloride monohydrate, 100-600 mg / L of L-cystine dihydrochloride, 200-1200 mg / L of L-glutamic acid, 500-1500 mg / L of L-histidine, 500-1500 mg / L of L-isoleucine, 500-1500 mg / L of 1800mg / L of L-leucine, 800-2000mg / L of L-lysine monohydrochloride, 100-700mg / L of L-methionine, 200-500mg / L of L-phenylalanine, 150-1000mg / L of L-proline, 500-1500mg / L of L-serine, 400-1200mg / L of L-threonine, 200-1000mg / L of L-tryptophan, 225-1350mg / L of L-tyrosine disodium salt and 100-300mg / L of L-valine; Preferably, the amino acid comprises 500-800 mg / L of L-arginine, 1000-2000 mg / L of L-asparagine monohydrate, 700-1000 mg / L of L-aspartic acid, 100-250 mg / L of L-cysteine monohydrochloride monohydrate, 100-400 mg / L of L-cystine dihydrochloride, 400-1000 mg / L of L-glutamic acid, 700-1100 mg / L of L-histidine, 600-1300 mg / L of L-isoleucine, 900-1600 mg / L of mg / L of L-leucine, 1000-1600 mg / L of L-lysine monohydrochloride, 300-600 mg / L of L-methionine, 250-400 mg / L of L-phenylalanine, 300-900 mg / L of L-proline, 700-1000 mg / L of L-serine, 650-900 mg / L of L-threonine, 400-950 mg / L of L-tryptophan, 500-900 mg / L of L-tyrosine disodium salt and 150-275 mg / L of L-valine; More preferably, the composition comprises 600 mg / L of L-arginine, 1800 mg / L of L-asparagine monohydrate, 800 mg / L of L-aspartic acid, 200 mg / L of L-cysteine monohydrochloride monohydrate, 300 mg / L of L-cystine dihydrochloride, 500 mg / L of L-glutamic acid, 800 mg / L of L-histidine, 700 mg / L of L-isoleucine, 1500 mg / L of g / L of L-leucine, 1500 mg / L of L-lysine monohydrochloride, 500 mg / L of L-methionine, 300 mg / L of L-phenylalanine, 600 mg / L of L-proline, 800 mg / L of L-serine, 800 mg / L of L-threonine, 500 mg / L of L-tryptophan, 700 mg / L of L-tyrosine disodium salt and 200 mg / L of L-valine.
5. The culture medium for CHO cell culture according to any one of claims 1 to 4, characterized in that: The nucleosides / nucleoside compounds contained in the culture medium include: 0.05-0.75 mg / L thymidine, 5.00-11.0 mg / L hypoxanthine monosodium salt, 1.25-9.5 mg / L cytosine, 2.5-9.0 mg / L guanine, 1.3-8.0 mg / L thymine, 0.5-8.5 mg / L adenine, 1.0-12 mg / L deoxycytidine 5'-monophosphate, 1.5-6.5 mg / L adenosine 5'-monophosphate monohydrate and 2.00-8.00 mg / L 2'-deoxyguanosine monohydrate; Preferably, the present invention comprises 0.10-0.55 mg / L of thymidine, 8.0-10.0 mg / L of hypoxanthine monosodium salt, 3.5-5.5 mg / L of cytosine, 3.0-4.5 mg / L of guanine, 2.5-6.0 mg / L of thymine, 1.0-6.0 mg / L of adenine, 3.0-7.0 mg / L of deoxycytidine 5'-monophosphate, 2.0-5.0 mg / L of adenosine 5'-monophosphate monohydrate and 2.0-6.0 mg / L of 2'-deoxyguanosine monohydrate; More preferably, it comprises 0.2 mg / L thymidine, 10 mg / L hypoxanthine monosodium salt, 4 mg / L cytosine, 4 mg / L guanine, 4 mg / L thymine, 4 mg / L adenine, 4 mg / L deoxycytidine 5'-monophosphate, 4 mg / L adenosine 5'-monophosphate monohydrate and 4 mg / L 2'-deoxyguanosine monohydrate; The fatty acids contained in the culture medium include: 0.0005-0.0030 mg / L arachidonic acid, 0.0020-0.10 mg / L linoleic acid, 0.0035-0.016 mg / L linolenic acid, 0.0028-0.035 mg / L myristic acid, 0.0045-0.018 mg / L oleic acid, 0.0045-0.020 mg / L palmitic acid and 0.005-0.012 mg / L stearic acid; Preferably, it comprises 0.0010-0.0020 mg / L of arachidonic acid, 0.0035-0.10 mg / L of linoleic acid, 0.0055-0.009 mg / L of linolenic acid, 0.004-0.01 mg / L of myristic acid, 0.0065-0.010 mg / L of oleic acid, 0.005-0.015 mg / L of palmitic acid and 0.006-0.0012 mg / L of stearic acid; More preferably, it comprises 0.0016 mg / L arachidonic acid, 0.008 mg / L linoleic acid, 0.008 mg / L linolenic acid, 0.008 mg / L myristic acid, 0.008 mg / L oleic acid, 0.008 mg / L palmitic acid and 0.008 mg / L stearic acid; Other substances contained in the culture medium include: 100-300 mg / L of choline chloride, 20-70 mg / L of dextran sulfate sodium salt, 70-130 mg / L of ethanolamine hydrochloride and 0.06-1.1 mg / L of 1,4-butanediamine dihydrochloride; Preferably, it comprises 150-250 mg / L of choline chloride, 40-70 mg / L of dextran sulfate sodium salt, 80-110 mg / L of ethanolamine hydrochloride and 0.4-0.9 mg / L of 1,4-butanediamine dihydrochloride; More preferably, it comprises 200 mg / L of choline chloride, 60 mg / L of dextran sulfate sodium salt, 100 mg / L of ethanolamine hydrochloride and 0.5 mg / L of 1,4-butanediamine dihydrochloride; The sugars contained in the culture medium include 5000-15000 mg / L of glucose, preferably 8000-11000 mg / L of glucose, and more preferably 10000 mg / L of glucose.
6. The culture medium for CHO cell culture according to any one of claims 1 to 5, characterized in that: The culture medium also includes a buffer substance and an anti-shear substance; Preferably, the buffer substance comprises sodium bicarbonate, and the anti-shear substance comprises Pluronic F68; Optionally, the content of sodium bicarbonate contained in the culture medium is 1000-3700 mg / L, preferably 1500-3500 mg / L, more preferably 2000 mg / L; Optionally, the content of PluronicF68 contained in the culture medium is 1250-3600 mg / L, preferably 1600-2500 mg / L, and more preferably 2000 mg / L.
7. A method for culturing CHO cells, the method comprising the following steps: (1) Cell recovery of CHO cells; (2) performing seed expansion culture on the cells revived in step (1); (3) First stage culture: according to the initial inoculation density (1.1±0.3)×10 6 The CHO cells obtained by seed expansion culture in step (2) were inoculated into the seed culture medium for culture at a temperature of 36.5±0.5°C and a stirring speed of 180-220 r / min. On the second day of culture, perfusion culture with the seed culture medium was started until the viable cell density reached 20.0×10 6 / mL or more, enter the second stage of cultivation; (4) Second stage culture: perfusion culture using the culture medium described in any one of claims 1 to 6, when the viable cell density is greater than 60.0×10 6 / mL, cool to 33-35℃, adjust the speed to 230-280r / min, and maintain the viable cell density at 100.0×10 6 Pieces / mL; Preferably, the seed culture medium is CD CHO medium; Optionally, during the culture process, the dissolved oxygen is controlled to 20% to 80%, preferably 50%; the pH value is controlled to 7.00±0.35; Optionally, the first stage culture time is 4 to 6 days in total.
8. The method for culturing CHO cells according to claim 7, characterized in that: The specific operation of cell recovery in step (1) is as follows: taking out the seed cells from the -80°C refrigerator for recovery, inoculating them into CD CHO culture medium, and culturing them at 36.5±0.5°C, 6.0±1.0% CO2, and 130±10 r / min for 2 to 4 days; The specific operation of the seed expansion culture in step (2) is: the revived cells obtained in step (1) are cultured at a rate of 0.3 to 0.7×10 6 Inoculate the cells at a density of 100 cells / mL into a shake flask containing CD CHO medium, and culture at 36.5±0.5°C, 6.0±1.0% CO2, and 130±10 r / min for 2 to 4 days. Follow this step to gradually expand the seed cells in a shake flask of 250 to 2000 mL; In the step (3), starting from the second day of culture, the seed culture medium is perfused at a rate of 0.5 VVD, and then the perfusion rate is increased by 0.5 VVD every day to no more than 2.0 VVD; In the step (4), the culture medium according to any one of claims 1 to 6 is used for perfusion culture at a rate of 0.5 VVD; when the glucose concentration in the reaction system is lower than 2.00 g / L, glucose is added to maintain the glucose concentration in the reaction system not lower than 2.00 g / L, and when the glucose concentration is higher than 3.00 g / L, the amount of glucose added is gradually reduced until the addition stops; optionally, when the glucose concentration is lower than 2.00 g / L, the amount of glucose added is increased in units of 1.00 g / L / day until the concentration is no longer lower than 2.00 g / L; optionally, when the glucose concentration is greater than 3.00 g / L, the amount of glucose added is reduced in units of 1.00 g / L / day.
9. The method for culturing CHO cells according to claim 7 or 8, characterized in that: The CHO cell is a CHO cell containing a protein encoding an exogenous protein; preferably, the CHO cell is CHO-K1, CHO-S, CHO-K1SV, CHO-GS or CHO-DG44, and the exogenous protein is an antibody; more preferably, the exogenous protein is a monoclonal antibody or a bispecific antibody.
10. Use of the culture medium for CHO cell culture according to any one of claims 1 to 6 in the expression of foreign proteins by CHO cells; preferably, the CHO cells are CHO-K1, CHO-S, CHO-K1SV, CHO-GS or CHO-DG44, and the foreign protein is an antibody; more preferably, the foreign protein is a monoclonal antibody or a bispecific antibody.
